JP2019504892A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504892A5
JP2019504892A5 JP2018560705A JP2018560705A JP2019504892A5 JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5 JP 2018560705 A JP2018560705 A JP 2018560705A JP 2018560705 A JP2018560705 A JP 2018560705A JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nucleic acid
acid encoding
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504892A (ja
Filing date
Publication date
Priority claimed from PCT/CN2016/087855 external-priority patent/WO2017133175A1/en
Application filed filed Critical
Publication of JP2019504892A publication Critical patent/JP2019504892A/ja
Publication of JP2019504892A5 publication Critical patent/JP2019504892A5/ja
Pending legal-status Critical Current

Links

JP2018560705A 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞 Pending JP2019504892A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016073489 2016-02-04
CNPCT/CN2016/073489 2016-02-04
PCT/CN2016/087855 WO2017133175A1 (en) 2016-02-04 2016-06-30 Engineered mammalian cells for cancer therapy
CNPCT/CN2016/087855 2016-06-30
PCT/CN2017/072723 WO2017133633A1 (en) 2016-02-04 2017-01-26 Engineered mammalian cells for cancer therapy

Publications (2)

Publication Number Publication Date
JP2019504892A JP2019504892A (ja) 2019-02-21
JP2019504892A5 true JP2019504892A5 (https=) 2020-03-05

Family

ID=59499323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560705A Pending JP2019504892A (ja) 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞

Country Status (5)

Country Link
US (1) US20190038671A1 (https=)
EP (1) EP3411079A4 (https=)
JP (1) JP2019504892A (https=)
CN (1) CN108883202A (https=)
WO (2) WO2017133175A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
AU2018223211B2 (en) * 2017-02-21 2025-02-27 Adelaide university T cells expressing chemokine receptors for treating cancer
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN110536700A (zh) * 2017-04-19 2019-12-03 南加利福尼亚大学 用于治疗癌症的组合物和方法
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
AU2018329741B2 (en) * 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
US12023353B2 (en) * 2017-10-18 2024-07-02 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
CN111971394B (zh) * 2018-02-15 2024-05-28 内盖夫生物技术国家研究所有限公司 嵌合抗原受体的肿瘤环境特异性表达
CN111867598A (zh) * 2018-03-13 2020-10-30 国立大学法人大阪大学 肿瘤免疫赋活剂
EP3781176A4 (en) * 2018-04-09 2022-05-25 The Trustees of the University of Pennsylvania METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
CN108913718A (zh) * 2018-07-20 2018-11-30 苏州茂行生物科技有限公司 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
WO2020049496A1 (en) * 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification
EP3850013A4 (en) 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN113226335B (zh) * 2018-12-06 2023-10-13 广东天科雅生物医药科技有限公司 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法
KR20220030205A (ko) * 2019-02-08 2022-03-10 디앤에이 투포인토 인크. 면역 세포의 트랜스포존 기반 변형
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
WO2020172553A1 (en) * 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US20220175833A1 (en) * 2019-03-07 2022-06-09 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
US20220204575A1 (en) * 2019-04-23 2022-06-30 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
US20220291203A1 (en) * 2019-07-25 2022-09-15 Immunowake Inc. Methods of measuring cell-mediated killing by effectors
CN114450397A (zh) * 2019-08-01 2022-05-06 纪念斯隆-凯特琳癌症中心 用于改善免疫疗法的细胞及其用途
WO2021041920A1 (en) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
IL292355A (en) * 2019-10-22 2022-06-01 Alloplex Biotherapeutics Compositions and methods for in vitro activation and expansion of serial killer t-cell populations and passive vaccination of a cancer patient with tumor cell-killing cells
JP7817159B2 (ja) * 2019-11-08 2026-02-18 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 炎症状態及び変性疾患を処置するために操作された間葉系幹細胞を使用する方法及び材料
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021144338A1 (en) * 2020-01-14 2021-07-22 Adaptimmune Limited Method of treatment of cancer or tumour
KR20220159989A (ko) * 2020-02-26 2022-12-05 바이오그래프 55, 인크. C19 c38 이중특이적 항체
CN115335087A (zh) * 2020-04-01 2022-11-11 南京传奇生物科技有限公司 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法
WO2022005994A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center C825 expressing immune cells and diagnostic uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
AU2021334950A1 (en) * 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
EP4359514A4 (en) * 2021-06-24 2025-03-26 Georgia Tech Research Corporation METHODS AND COMPOSITIONS FOR REMOTE CONTROL OF T CELL THERAPIES BY THERMAL TARGETING
CN113789299B (zh) * 2021-10-18 2023-03-24 新鲁细胞生物科技(海南)有限公司 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
WO2024077270A1 (en) * 2022-10-07 2024-04-11 Senti Biosciences, Inc. Armed chimeric receptors and methods of use thereof
WO2024107410A1 (en) * 2022-11-14 2024-05-23 The Board Of Trustees Of The Leland Stanford Junior University Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival
WO2025081190A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Image guided car t cell therapy to treat brain tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215964A (en) * 1991-06-03 1993-06-01 Immunobiology Research Institute, Inc. Peptides useful in regulating the immune and nervous systems
KR20010031762A (ko) * 1997-11-03 2001-04-16 추후제출 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법
CN101899114A (zh) * 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
NZ569541A (en) * 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6647868B2 (ja) * 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
ES2857226T3 (es) * 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
JP2017528433A (ja) * 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
KR20180019725A (ko) * 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제

Similar Documents

Publication Publication Date Title
JP2019504892A5 (https=)
Liu et al. Turning cold tumors into hot tumors by improving T-cell infiltration
Dougan et al. Cancer immunotherapy: beyond checkpoint blockade
Demaria et al. Harnessing innate immunity in cancer therapy
Mardi et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
JP7162632B2 (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
West et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
Dammeijer et al. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Wang et al. What happens to the immune microenvironment after PD-1 inhibitor therapy?
JP2019500909A5 (https=)
Zamarin et al. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
Draghiciu et al. Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
Huang et al. Innovative strategies to advance CAR T cell therapy for solid tumors
JP2019501670A5 (https=)
Cervera-Carrascon et al. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
JP2026015423A (ja) ＩＦＮ－γの抗腫瘍補助薬の調製への応用
JP2019531293A (ja) Ｐｄ−１ペプチド阻害剤
Hughes et al. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma
Hu et al. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them
Vo et al. Cellular immunotherapy in multiple myeloma
IL295952A (en) Lymphocyte population and methods for their preparation
Msaouel et al. Immune checkpoint therapy in head and neck cancers
DeLucas et al. Recapitulating the qualities of HIV-specific CD8+ T cells from spontaneous controllers
Liu et al. Prospects and applications of NK therapy in the treatment of gliomas
Lasek et al. Interleukin 12: Antitumor activity and immunotherapeutic potential in oncology